Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting

NEXT STORY
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
PREV STORY
SetPoint Medical to Present Results From The U.S. Pilot Study in Rheumatoid Arthritis Patients at European Congress of Rheumatology (EULAR) 2019
Subscribe to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

The North American Creatinine Measurement Market is expected to reach US$ 269.75 million in 2027 from US$ 148.79 million in 2019

author_avatar
NASDAQ Market News

Monoclonal Antibodies Market Trends 2021 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research

author_avatar
NASDAQ Market News

Everest Medicines Announces Approval of Xerava™ from the Health Science Authority in Singapore for the Treatment of Complicated Intra-Abdominal Infections

author_avatar
NASDAQ Market News